On July 9, 2018 LIDDS reported that it has agreed to transfer the licensing agreement for Liproca Depot in China to Jiangxi Puheng Pharmaceuticals Ltd following a request from the owners of Jiangsu Ambition Medical (Press release, Lidds, JUL 9, 2018, View Source [SID1234555912]). The change of legal entity will not impact the time lines or Liproca Depot activities and development in China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jiangxi Puheng Pharmaceuticals Ltd is backed by the same owners and has access to the same substantial competencies and capabilities as Jiangsu Ambition Medical.

Jiangxi Puheng Pharmaceuticals is spun out of Jiangxi Jiminkexin Group which ranks in the top 10 pharmaceutical companies of China and has collaboration agreements with international pharma companies. The company and its owners view NanoZolid technology and specifically the Liproca Depot product as a very promising treatment for prostate cancer.

Prostate cancer is the fastest growing cancer disease in China, why research and development in this field is of great importance. Jiangxi Puheng Pharmaceuticals expects that the sales of Liproca Depot will reach yearly sales of 50 000 to 70 000 treatments in 3 to 5 years after launch.